Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS) (MAIDS)
Microvascular Angina
About this trial
This is an interventional treatment trial for Microvascular Angina focused on measuring Coronary Blood Flow Reserve, Microvascular Angina, Compound Danshen Dripping Pill, echocardiography
Eligibility Criteria
Inclusion criteria: with typical symptoms of exertional angina; coronary CTA or angiography with normal coronary artery or <50% stenosis, or <50% residual coronary stenosis after revascularization; resting electrocardiogram or During exercise stress, it was found that the ST segment had an ischemic downward shift (the horizontal or downward slope after the J-point shift > 0.1 mv, lasting 0.08 s); Transthoracic ultrasound examination of blood in the anterior descending coronary artery before and after intravenous injection of adenosine Flow reserve check CFR<2.5; The patient himself agrees to participate in this study. Exclusion criteria Less than 30 years old or more than 75 years old; Have a history of carotid endarterectomy or stent implantation, and have a history of stroke; Myocarditis, pericardial disease, valvular disease, cardiomyopathy; Difficult to control diabetes mellitus (fasting blood glucose>7.0 mmol/L); Uncontrolled hypertension (SBP>150 mmHg and/or DBP>90 mmHg); Familial hypercholesterolemia; Multiple Takayasu arteritis; Those who are pregnant or lactating, or have fertility intention within one year, or have not taken effective contraceptive measures during the childbearing period; Abnormal liver function (the level of serum GPT is 3.0 times higher than the upper limit of normal value) or abnormal renal function (the level of serum creatinine is more than 2 mg/dl); Other respiratory, digestive, blood, infection, immunity, endocrine, neuropsychiatric, tumor diseases with clinical significance that may cause serious danger to patients; Taking traditional Chinese medicine preparations of K channel opener, promoting blood circulation and removing blood stasis to improve microcirculation; Allergies to intra arterial injection of contrast agents, blood and blood products; Patients who are participating in other clinical studies.
Sites / Locations
- Qilu Hospital of Shandong UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Compound Danshen Dropping Pills
Placebo
Treatment group: Compound Danshen Dropping Pills (Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day, 20 capsules each time.
Placebo group: placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.